Quality of Life Study in Participants With IPF Under Pirfenidone Treatment (PNEUMON)

Roche

Status: Completed

Conditions: Idiopathic Pulmonary Fibrosis

Treatments: Drug: Pirfenidone

Study type: Observational

Funder types: Industry

Identifiers

NCT03115619

ML39259

Details and patient eligibility

About

This multicenter, post-marketing, observational study will evaluate quality of life in participants with Idiopathic Pulmonary Fibrosis (IPF) under treatment with pirfenidone (Esbriet).

Enrollment: 102 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult participants for whom pirfenidone has already been prescribed for IPF no more than 4 weeks prior to enrollment, according to their physicians' clinical decision and the terms in the SmPC

Exclusion criteria

• Participants who are participating in an interventional study or have received any investigational agent in the past 4 weeks

Trial design

102 participants in 1 patient group

Participants With IPF

Description:

Observational data of participants with IPF under treatment with pirfenidone will be collected from the medical records as a part of their routine clinical visits at 12-week interval until study completion or early withdrawal (up to Week 52).

Treatment:

Drug: Pirfenidone